In order to make sure that the patients who need their cutting-edge treatments the most receive them, pharmaceutical companies frequently face enormous challenges. Regulatory clearances, pricing negotiations, and reimbursement rules typically play a complex role in enabling market access to all advances. Patient advocacy organizations (PAOs) are essential in negotiating these complications since they advocate for patient’s needs and offer valuable insights that can impact drug research, shape healthcare legislation, and ease market access.[1]
It is normally necessary to follow specific best practices while interacting with PAOs in order to guarantee efficient cooperation and patient needs alignment. Maintaining alignment with patient objectives throughout the product lifecycle is made possible by early and ongoing interaction with PAOs, which guarantees the integration of patient viewpoints from the beginning of the medication development process. For example, clinical trial designs and post-market support programs were influenced by Roche’s early discussions with PAOs on its treatment for hemophilia. Additionally, open communication is essential because it fosters trust with PAOs by providing information on safety data, clinical trials, and potential risks and benefits. An example of this emphasis on openness may be seen in Gilead’s collaboration with PAOs in the development of HIV medications, which eventually aided in winning over patient confidence and advocacy support.[1,2]
Through PAOs, patient insights can be integrated into clinical trial designs, patient support programs, and market entry tactics, improving the acceptance and relevance of health innovations. Companies and PAOs working together to advocate for novel medicines can have a significant impact on policy and reimbursement decisions by communicating the benefits of these therapies in a way that legislators and payers understand. One instance is the partnership between Novartis and PAOs on therapies for spinal muscular atrophy, which aided in promoting more accessibility and advantageous reimbursement guidelines.[3]
Interacting with PAOs may present a number of difficulties as well. First of all, the goals and objectives of PAOs are frequently varied and may not always coincide with those of pharmaceutical corporations. Interacting with PAOs may present a number of difficulties as well. Balancing these conflicting goals calls for sensitivity and negotiation abilities. Furthermore, a lot of PAOs have limited funding, which can limit their capacity to interact completely with pharmaceutical corporations. Concerns about compliance and regulations also come up a lot in these encounters. Maintaining ethical standards and avoiding conflicts of interest need interactions to be compliant with regulatory frameworks. Maintaining ethical standards and avoiding conflicts of interest need interactions to be compliant with regulatory frameworks.[4,5]
Pharmaceutical businesses can take numerous innovative steps to improve their market access strategy by interacting with PAOs. Building successful ties with PAOs involves doing research, selecting groups pertinent to the therapy area or illness state, and giving priority to those that have a proven track record of patient participation and advocacy efforts. Early engagement of PAOs in the medication development process guarantees the integration of patient viewpoints from the outset of product lifecycles, hence augmenting the pertinence and acceptability of novel medicines. By working together, patient education and support programs can better meet the needs and preferences of patients by using the resources and expertise of PAOs in the creation of materials and activities. By partnering with PAOs, businesses may gain vital access to patient communities and customize their market access tactics according to a better understanding of patient preferences and needs. Ultimately, showcasing a business’s actual commitment to meeting patient requirements and enhancing healthcare outcomes is demonstrated by forming solid partnerships with PAOs and exhibiting a commitment to patient-centered care.[6]
Market access strategies that are successful must interact with PAOs. Early and ongoing involvement, open communication, and using patient perspectives are examples of best practices. Pharmaceutical businesses may provide patient requirements at the forefront of healthcare developments and improve market access by using novel strategies and establishing meaningful collaborations.
Become A Certified HEOR Professional – Enrol yourself here!
References:
- Roche position on working with patient groups [Internet]. Available from: https://assets.roche.com/f/176343/x/d9f667b276/roche_position_on_working_with_patient_groups.pdf.
- Gilead partners with CHAI and Penta to improve treatment and adherence rates among children with HIV in low- and middle-income countries [Internet]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-partners-with-chai-and-penta-to-improve-treatment-and-adherence-rates-among-children-with-hiv-in-low-and-middle-income-countries.
- Newborn screening for spinal muscular atrophy (SMA) [Internet]. Available from: https://www.novartis.com/diseases/spinal-muscular-atrophy-sma/newborn-screening-spinal-muscular-atrophy-sma.
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action; Martinez RM, Osei-Anto HA, McCormick M, editors. Addressing sickle cell disease: a strategic plan and blueprint for action. Washington (DC): National Academies Press (US); 2020 Sep 10. Community engagement and patient advocacy. Available from: https://www.ncbi.nlm.nih.gov/books/NBK566476/.
- Kanter GP. Extending the Sunshine Act from physicians to patient advocacy organizations. Am J Public Health. 2018;108(8):978-979. doi:10.2105/AJPH.2018.304520.
- Rach C, Lukas J, Müller R, Sendler M, Simon P, Salloch S. Involving patient groups in drug research: a systematic review of reasons. Patient Prefer Adherence. 2020;14:587-597. doi:10.2147/PPA.S232499.